Literature DB >> 23043192

Long-term follow-up of patients with hypoparathyroidism.

Deborah M Mitchell1, Susan Regan, Michael R Cooley, Kelly B Lauter, Michael C Vrla, Carolyn B Becker, Sherri-Ann M Burnett-Bowie, Michael Mannstadt.   

Abstract

CONTEXT: Despite tremendous interest in hypoparathyroidism, large cohort studies describing typical treatment patterns, laboratory parameters, and rates of complications are lacking.
OBJECTIVE: Our objective was to characterize the course of disease in a large cohort of hypoparathyroid patients. DESIGN AND
SETTING: We conducted a chart review of patients with permanent hypoparathyroidism identified via a clinical patient data registry. Patients were seen at a Boston tertiary-care hospital system between 1988 and 2009. PATIENTS: We identified 120 patients. Diagnosis was confirmed by documented hypocalcemia with a simultaneous low or inappropriately normal PTH level for at least 1 yr. Mean age at the end of the observation period was 52 ± 19 (range 2-87) yr, and the cohort was 73% female. MAIN OUTCOME MEASURE: We evaluated serum and urine laboratory results and renal and brain imaging.
RESULTS: We calculated time-weighted average serum calcium measurements for all patients. The time-weighted average for calcium was between 7.5 and 9.5 mg/dl for the majority (88%) of patients. Using linear interpolation, we estimated the proportion of time within the target calcium range for each patient with a median of 86% (interquartile range 67-98%). Of those with a 24-h urine collection for calcium (n = 53), 38% had at least one measurement over 300 mg/d. Of those with renal imaging (n = 54), 31% had renal calcifications, and 52% of those with head imaging (n = 31) had basal ganglia calcifications. Rates of chronic kidney disease stage 3 or higher were 2- to 17-fold greater than age-appropriate norms.
CONCLUSIONS: Hypoparathyroidism and its treatment carry a large burden of disease. Renal abnormalities are particularly common.

Entities:  

Mesh:

Year:  2012        PMID: 23043192      PMCID: PMC3513540          DOI: 10.1210/jc.2012-1808

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  30 in total

1.  Genetic developments in hypoparathyroidism.

Authors:  R V Thakker
Journal:  Lancet       Date:  2001-03-31       Impact factor: 79.321

2.  [Prevalence and clinical significance of computerized tomography verified idiopathic calcinosis of the basal ganglia].

Authors:  T Gomille; R A Meyer; P Falkai; W Gaebel; T Königshausen; F Christ
Journal:  Radiologe       Date:  2001-02       Impact factor: 0.635

Review 3.  Hyperparathyroid and hypoparathyroid disorders.

Authors:  S J Marx
Journal:  N Engl J Med       Date:  2000-12-21       Impact factor: 91.245

4.  Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism.

Authors:  Ravinder Goswami; Raju Sharma; Vishnubhatla Sreenivas; Nandita Gupta; Arthi Ganapathy; Sathi Das
Journal:  Clin Endocrinol (Oxf)       Date:  2012-08       Impact factor: 3.478

5.  Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research.

Authors:  John P Bilezikian; Aliya Khan; John T Potts; Maria Luisa Brandi; Bart L Clarke; Dolores Shoback; Harald Jüppner; Pierre D'Amour; John Fox; Lars Rejnmark; Leif Mosekilde; Mishaela R Rubin; David Dempster; Rachel Gafni; Michael T Collins; Jim Sliney; James Sanders
Journal:  J Bone Miner Res       Date:  2011-10       Impact factor: 6.741

6.  Activating mutations in the calcium-sensing receptor: genetic and clinical spectrum in 25 patients with autosomal dominant hypocalcaemia - a German survey.

Authors:  Friedhelm Raue; Josef Pichl; Helmuth-G Dörr; Dirk Schnabel; Peter Heidemann; Gerhard Hammersen; Cornelia Jaursch-Hancke; Reinhard Santen; Christof Schöfl; Martin Wabitsch; Christine Haag; Egbert Schulze; Karin Frank-Raue
Journal:  Clin Endocrinol (Oxf)       Date:  2011-12       Impact factor: 3.478

7.  Twenty-four-hour urine chemistries and the risk of kidney stones among women and men.

Authors:  G C Curhan; W C Willett; F E Speizer; M J Stampfer
Journal:  Kidney Int       Date:  2001-06       Impact factor: 10.612

8.  Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism.

Authors:  Karen K Winer; Bo Zhang; Joseph A Shrader; Donna Peterson; Michaele Smith; Paul S Albert; Gordon B Cutler
Journal:  J Clin Endocrinol Metab       Date:  2011-11-16       Impact factor: 5.958

9.  Mutations in SLC20A2 link familial idiopathic basal ganglia calcification with phosphate homeostasis.

Authors:  Cheng Wang; Yulei Li; Lei Shi; Jie Ren; Monica Patti; Tao Wang; João R M de Oliveira; María-Jesús Sobrido; Beatriz Quintáns; Miguel Baquero; Xiaoniu Cui; Xiang-Yang Zhang; Lianqing Wang; Haibo Xu; Junhan Wang; Jing Yao; Xiaohua Dai; Juan Liu; Lu Zhang; Hongying Ma; Yong Gao; Xixiang Ma; Shenglei Feng; Mugen Liu; Qing K Wang; Ian C Forster; Xue Zhang; Jing-Yu Liu
Journal:  Nat Genet       Date:  2012-02-12       Impact factor: 38.330

10.  Familial isolated hypoparathyroidism caused by a mutation in the gene for the transcription factor GCMB.

Authors:  C Ding; B Buckingham; M A Levine
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

View more
  94 in total

Review 1.  Hypoparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

2.  Pharmacodynamic Actions of a Long-Acting PTH Analog (LA-PTH) in Thyroparathyroidectomized (TPTX) Rats and Normal Monkeys.

Authors:  Masaru Shimizu; Eri Joyashiki; Hiroshi Noda; Tomoyuki Watanabe; Makoto Okazaki; Miho Nagayasu; Kenji Adachi; Tatsuya Tamura; John T Potts; Thomas J Gardella; Yoshiki Kawabe
Journal:  J Bone Miner Res       Date:  2016-05-23       Impact factor: 6.741

3.  Effect of incidental parathyroidectomy on postoperative calcium levels after to-tal thyroidectomy.

Authors:  M Doulaptsi; D Ierodiakonou; E Prokopakis; N Stanitsa; A Rogdakis; A Karatzanis
Journal:  Hippokratia       Date:  2020 Apr-Jun       Impact factor: 0.471

4.  Parathyroid hormone therapy for hypoparathyroidism.

Authors:  Natalie E Cusano; Mishaela R Rubin; John P Bilezikian
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2014-09-10       Impact factor: 4.690

Review 5.  Diagnosis and management of hypocalcemia.

Authors:  Jessica Pepe; Luciano Colangelo; Federica Biamonte; Chiara Sonato; Vittoria Carmela Danese; Veronica Cecchetti; Marco Occhiuto; Valentina Piazzolla; Viviana De Martino; Federica Ferrone; Salvatore Minisola; Cristiana Cipriani
Journal:  Endocrine       Date:  2020-05-04       Impact factor: 3.633

6.  Parathyroid gland: complications of HPT.

Authors:  Carol Wilson
Journal:  Nat Rev Endocrinol       Date:  2012-11-13       Impact factor: 43.330

7.  Iatrogenic/post-surgical hypoparathyroidism: where do we go from here?

Authors:  Saba P Balasubramanian
Journal:  Endocrine       Date:  2014-08-23       Impact factor: 3.633

Review 8.  Use of parathyroid hormone in hypoparathyroidism.

Authors:  N E Cusano; M R Rubin; D Irani; J Sliney; J P Bilezikian
Journal:  J Endocrinol Invest       Date:  2013-12       Impact factor: 4.256

Review 9.  The use of ICG enhanced fluorescence for the evaluation of parathyroid gland preservation.

Authors:  Pornpeera Jitpratoom; Angkoon Anuwong
Journal:  Gland Surg       Date:  2017-10

Review 10.  Bone imaging in hypoparathyroidism.

Authors:  B C Silva; M R Rubin; N E Cusano; J P Bilezikian
Journal:  Osteoporos Int       Date:  2016-08-30       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.